GAL and neoplasm: Importantly, we were able to differentiate the source of Gal-1 (tumor and microenvironment versus tumor alone): firstly, a blocking anti-Gal-1 mAb was added to the mix (total Gal-1 inhibition independently of its source is to be expected); alternatively, we used 22Rv1 tumor cells transduced with a human specific Gal-1 shRNA-coding lentivirus (thus inhibiting tumoral Gal-1 expression alone).